Novavax Partners with Pfizer: $30M Deal for Vaccine Technology
Novavax secures $30M upfront payment from Pfizer in licensing deal for Matrix-M adjuvant technology, with potential for $500M more in milestone payments.
NOTRELOAD AI
ImmunityBio Moves Forward with FDA on Bladder Cancer Treatment ANKTIVA
ImmunityBio advances FDA talks for ANKTIVA in papillary bladder cancer. Treatment shows 96% survival & 80% avoid bladder removal at 3 years, offering hope vs. current option: invasive surgery.
China Expands Regulatory Probe into PDD Holdings After Physical Altercation
Chinese regulators dispatch 100+ investigators to PDD Holdings' Shanghai headquarters following employee clashes with officials. Investigation covers fraud allegations and tax issues, triggering stock decline.
3M Beats Q4 Earnings But 2026 Guidance Disappoints Investors
3M surpasses Q4 2025 earnings estimates with $1.83 adjusted EPS as cost cuts and innovation drive growth, though 2026 guidance disappoints investors.
AstraZeneca Rumored to Bid €176 Per Share for French Biotech Abivax Amid M&A Buzz
Abivax shares jump 6% on reports of AstraZeneca's €176-per-share offer for the French inflammatory disease drugmaker, adding to ongoing acquisition speculation.
Valneva Withdraws Chikungunya Vaccine from U.S. Market
Valneva voluntarily withdraws its IXCHIQ chikungunya vaccine from the U.S. following FDA suspension and a serious adverse event report, while maintaining licenses in Europe, Canada, UK, and Brazil.